MAD2L1 and neoplasm: Interestingly, when all ovarian cancer studies are removed, as shown in Figure 2, a significant pooled HR of 1.59 for risk of all-cause mortality in patients with high expressing MAD2 tumours was evident compared to those with low expressing MAD2 tumours (95% CI, 1.17–2.17; P = 0.003), but still incurred high heterogeneity (I2 = 65%, P = 0.001).